Using the company "Oramed Pharmaceutical" Develop a set of financial ratios and provide an opinion on the financial health of the company. Highlight the major financial and explain the critical areas of the company.

Comparison of Fiscal 2020 to Fiscal 2019 The following table summarizes certain statements of operations data for us for the twelve month periods ended August 31, 2020 and 2019: Year ended August 31, 2020 2019 Operating Data: Revenues Cost of revenues Research and development expenses General and administrative expenses Financial income, net Loss before taxes on income Taxes on income Net loss for the year (dollar amounts in thousands) $ 2,710 $ 2,703 90 10,235 13,522 4,232 3,722 246 576 11,511 14,055 300 11,511 14,355 $ Loss per common share - basic and diluted Weighted average common shares outstanding 0.56 $ 20,532,347 0.82 17,454,489 2020 2019* As of August 31, 2018 (in thousands of dollars) 2017 2016 $ $ $ $ Balance Sheet Data: Cash, cash equivalents, short-term deposits, restricted cash and marketable securities Other current assets Long-term deposits and other assets Long-term marketable securities Total assets Current liabilities Long-term liabilities Stockholders' equity 39,900 611 2 3,928 44,633 4,536 7,218 32,879 32,282 1,042 1 1,295 34,663 5,308 9,962 19,393 30,463 $ 574 13,575 2,785 47,397 4,553 11,732 31,112 20,138 159 16,262 2,151 38,712 5,165 14,309 19,238 31,032 198 11,070 530 42,830 3,621 13,019 26,190 Comparison of Fiscal 2020 to Fiscal 2019 The following table summarizes certain statements of operations data for us for the twelve month periods ended August 31, 2020 and 2019: Year ended August 31, 2020 2019 Operating Data: Revenues Cost of revenues Research and development expenses General and administrative expenses Financial income, net Loss before taxes on income Taxes on income Net loss for the year (dollar amounts in thousands) $ 2,710 $ 2,703 90 10,235 13,522 4,232 3,722 246 576 11,511 14,055 300 11,511 14,355 $ Loss per common share - basic and diluted Weighted average common shares outstanding 0.56 $ 20,532,347 0.82 17,454,489 2020 2019* As of August 31, 2018 (in thousands of dollars) 2017 2016 $ $ $ $ Balance Sheet Data: Cash, cash equivalents, short-term deposits, restricted cash and marketable securities Other current assets Long-term deposits and other assets Long-term marketable securities Total assets Current liabilities Long-term liabilities Stockholders' equity 39,900 611 2 3,928 44,633 4,536 7,218 32,879 32,282 1,042 1 1,295 34,663 5,308 9,962 19,393 30,463 $ 574 13,575 2,785 47,397 4,553 11,732 31,112 20,138 159 16,262 2,151 38,712 5,165 14,309 19,238 31,032 198 11,070 530 42,830 3,621 13,019 26,190